Chemistry:BL-1020

From HandWiki
Short description: Chemical compound
BL-1020
Perphenazine gamma-aminobutyrate.svg
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC25H33ClN4O2S
Molar mass489.08 g·mol−1
3D model (JSmol)

BL-1020 (perphenazine 4-aminobutanoate) is an investigational orally-active antipsychotic for the possible treatment of schizophrenia. The chemical is an ester of GABA and perphenazine; pharmacologically it acts as a D2 antagonist and GABA agonist. It has shown pro-cognitive effects in the trials.[1] In March 2013, it went into the II/III trial phase.[2] It has been introduced by BioLineRx, a biopharmaceutical development company.

References

  1. "Bl-1020, a new γ-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study". The Journal of Clinical Psychiatry 73 (9): e1168-74. September 2012. doi:10.4088/jcp.12m07642. PMID 23059159. 
  2. Biolinerx (Jan 7, 2013). "BioLineRx to Announce Interim Results of Phase II/III Trial for Schizophrenia Drug during week of March 18, 2013". Biolinerx. http://www.biolinerx.com/default.asp?pageid=16&itemid=166. 

{{Navbox | name = GABA receptor modulators | title = GABA receptor modulators | state = collapsed | bodyclass = hlist | groupstyle = text-align:center;

 | group1 = Ionotropic
 |  list1 = {{Navbox|subgroup
 | groupstyle = text-align:center
 | groupwidth = 5em
   | group1 = GABAA
   | list1  = 
   | group2 = GABAA
   | list2  = 
 }}
 | group2 = Metabotropic

| list2 =

 | below = 
See also
Receptor/signaling modulators
GABAA receptor positive modulators
GABA metabolism/transport modulators

}}